The future of animal models of invasive aspergillosis.

The diagnosis of invasive aspergillosis remains very difficult, coupled with limited treatment options. Animal models have been utilized to evaluate both the diagnosis and treatment of infection and to assess the pathogenicity and virulence of the organism. However, animal models have not been standardized and have been used in only a limited fashion for genomic evaluation in this disease. Extensive efforts are underway to expand significantly the Aspergillus genomic information. Thus, the standardization of animal models of invasive aspergillosis is critical to create a unified platform to enhance evaluation of newer genomic information and allow assessment of pathogenicity and virulence factors. Proposed models, supported by a recently awarded National Institutes of Health/National Institute of Allergy and Infectious Diseases contract, will be developed in close interaction with the extended Aspergillus community (including academia and industry) to answer key questions in this disease. The goal of this work is to provide the framework to evaluate genomic targets in animal models in order to improve the diagnosis and treatment of invasive aspergillosis that will ultimately result in improved outcomes of patients with this frequently fatal infection.

[1]  W. M. Foster,et al.  Value of an inhalational model of invasive aspergillosis. , 2004, Medical mycology.

[2]  S. Balajee,et al.  Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. , 2004, The Journal of infectious diseases.

[3]  E. Estey,et al.  β-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome , 2004 .

[4]  S. Filler,et al.  Novel Inhalational Murine Model of Invasive Pulmonary Aspergillosis , 2004, Antimicrobial Agents and Chemotherapy.

[5]  Steve A. Hernandez,et al.  Activity of Posaconazole Combined with Amphotericin B against Aspergillus flavus Infection in Mice: Comparative Studies in Two Laboratories , 2004, Antimicrobial Agents and Chemotherapy.

[6]  R. Soiffer,et al.  Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. , 2003, Blood.

[7]  T. Walsh,et al.  Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. , 2003, The Journal of infectious diseases.

[8]  D. Denning,et al.  Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. , 2003, Journal of Antimicrobial Chemotherapy.

[9]  J. Perfect,et al.  Newer antifungal therapy for emerging fungal pathogens. , 2003, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[10]  T. Patterson,et al.  Efficacy of Caspofungin Alone and in Combination with Voriconazole in a Guinea Pig Model of Invasive Aspergillosis , 2002, Antimicrobial Agents and Chemotherapy.

[11]  H. Einsele,et al.  Polymerase chain reaction detection of aspergillus DNA in experimental models of invasive aspergillosis. , 2002, The Journal of infectious diseases.

[12]  A. Francesconi,et al.  Antifungal Efficacy of Caspofungin (MK-0991) in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits: Pharmacokinetics, Drug Disposition, and Relationship to Galactomannan Antigenemia , 2002, Antimicrobial Agents and Chemotherapy.

[13]  D. Schmatz,et al.  Quantitative PCR Assay To MeasureAspergillus fumigatus Burden in a Murine Model of Disseminated Aspergillosis: Demonstration of Efficacy of Caspofungin Acetate , 2001, Antimicrobial Agents and Chemotherapy.

[14]  D. McMurray,et al.  Disease model: pulmonary tuberculosis. , 2001, Trends in molecular medicine.

[15]  J. Graybill The role of murine models in the development of antifungal therapy for systemic mycoses. , 2000, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[16]  M. Rinaldi,et al.  Efficacy of Voriconazole in a Guinea Pig Model of Disseminated Invasive Aspergillosis , 2000, Antimicrobial Agents and Chemotherapy.

[17]  William R. Kirkpatrick,et al.  Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes , 2000, Medicine.

[18]  W. Leisenring,et al.  Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. , 1997, The Journal of infectious diseases.

[19]  T. Patterson,et al.  Aspergillus antigen detection in the diagnosis of invasive aspergillosis. , 1995, The Journal of infectious diseases.

[20]  A. Francesconi,et al.  Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy , 1995, Antimicrobial agents and chemotherapy.

[21]  T. Walsh,et al.  Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis , 1994, Antimicrobial Agents and Chemotherapy.

[22]  M. Rinaldi,et al.  Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis , 1993, Antimicrobial Agents and Chemotherapy.

[23]  T. Patterson,et al.  Saperconazole therapy in a rabbit model of invasive aspergillosis , 1992, Antimicrobial Agents and Chemotherapy.

[24]  T. Patterson,et al.  Animal models: usefulness for studies of fungal pathogenesis and drug efficacy in aspergillosis. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  T. Patterson,et al.  Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis , 1991, Antimicrobial Agents and Chemotherapy.

[26]  T. Walsh,et al.  Fungus dose-dependent primary pulmonary aspergillosis in immunosuppressed mice , 1989, Infection and immunity.

[27]  F. Szoka,et al.  Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. , 1989, The Journal of infectious diseases.

[28]  J. Ryan,et al.  Effect of immunosuppression and amphotericin B on Aspergillus antigenemia in an experimental model. , 1988, The Journal of infectious diseases.

[29]  V. Andriole,et al.  The diagnosis of invasive aspergillosis by an enzyme-linked immunosorbent assay for circulating antigen. , 1985, The Journal of infectious diseases.

[30]  J. Graybill,et al.  Treatment of experimental murine aspergillosis with BAY n7133. , 1983, The Journal of infectious diseases.